Investment report on Arrowhead Research

BeaconEquity.com announces an investment report featuring Arrowhead Research Corp. (Nasdaq:ARWR). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/ARWR

Get our alerts BEFORE the rest of the market.  Follow us on Twitter: https://twitter.com/BeaconEquity

Arrowhead Research Corp. (ARWR) is a development stage nanotechnology company. The Company is focused on the electronics and biotech industries. ARWR owns two majority-owned operating subsidiaries, Unidym Inc. and Calando Pharmaceuticals Inc., three wholly owned, non-operating subsidiaries, Tego, Agonn and Masa Energy LLC, and has minority investments in two early-stage nanotechnology companies, Nanotope Inc. and Leonardo Biosystems Inc. On December 23, 2009, ARWR's wholly owned subsidiary Tego Biosciences Inc., completed the sale of all of its non-cash intellectual property assets (Tego IP) to Luna Innovations Inc.

Message Board Search for ARWR: http://www.boardcentral.com/boards/ARWR

In the report, the analyst notes:

"For the quarter ended December 31, 2009, ARWR reported revenue of $148,000, compared with $702,000 in the quarter ended December 31, 2008. The prior period revenue included $535,000 in proceeds from license fees and grants, which were not repeated in the current period. The sale of carbon nanotubes by Unidym comprised comparable revenue in both periods.

"ARWR recently announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals Inc. has demonstrated systemic delivery of siRNA and the successful 'silencing' of a widely recognized cancer gene via RNA interference (RNAi) in humans. This represents a breakthrough for Calando, its proprietary RONDEL™ delivery system, and the field of RNAi."